These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34813794)

  • 1. Advances in the development of antimicrobial peptides and proteins for inhaled therapy.
    Wang Y; Chang RYK; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2022 Jan; 180():114066. PubMed ID: 34813794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powder pharmaceutical biologics for inhalation therapy.
    Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
    Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial peptides towards clinical application: Delivery and formulation.
    Wang C; Hong T; Cui P; Wang J; Xia J
    Adv Drug Deliv Rev; 2021 Aug; 175():113818. PubMed ID: 34090965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalation Delivery of Host Defense Peptides (HDP) using Nano- Formulation Strategies: A Pragmatic Approach for Therapy of Pulmonary Ailments.
    Adlakha S; Sharma A; Vaghasiya K; Ray E; Verma RK
    Curr Protein Pept Sci; 2020; 21(4):369-378. PubMed ID: 31889487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
    Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
    Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.
    Mukker JK; Singh RS; Derendorf H
    Adv Drug Deliv Rev; 2015 May; 85():57-64. PubMed ID: 25770775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.
    Justo JA; Danziger LH; Gotfried MH
    Ther Adv Respir Dis; 2013 Oct; 7(5):272-87. PubMed ID: 23690368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation Approaches to Overcome Biopharmaceutical Limitations of Inhaled Peptides/Proteins.
    Onoue S; Suzuki H; Seto Y
    Curr Pharm Des; 2015; 21(27):3867-74. PubMed ID: 26290195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled antimicrobial therapy - barriers to effective treatment.
    Weers J
    Adv Drug Deliv Rev; 2015 May; 85():24-43. PubMed ID: 25193067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on parenteral delivery of peptides and proteins.
    Jain D; Mahammad SS; Singh PP; Kodipyaka R
    Drug Dev Ind Pharm; 2019 Sep; 45(9):1403-1420. PubMed ID: 31215293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy.
    Lee SH; Teo J; Heng D; Ng WK; Zhao Y; Tan RB
    J Pharm Sci; 2016 Apr; 105(4):1501-12. PubMed ID: 27019964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanofibers as drug-delivery systems for antimicrobial peptides.
    Sousa MGC; Rezende TMB; Franco OL
    Drug Discov Today; 2021 Aug; 26(8):2064-2074. PubMed ID: 33741497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.
    Zhou QT; Gengenbach T; Denman JA; Yu HH; Li J; Chan HK
    AAPS J; 2014 Jan; 16(1):37-47. PubMed ID: 24129586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romo1-Derived Antimicrobial Peptide Is a New Antimicrobial Agent against Multidrug-Resistant Bacteria in a Murine Model of Sepsis.
    Lee HR; You DG; Kim HK; Sohn JW; Kim MJ; Park JK; Lee GY; Yoo YD
    mBio; 2020 Apr; 11(2):. PubMed ID: 32291307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery Systems for Antimicrobial Peptides and Proteins: Towards Optimization of Bioavailability and Targeting.
    Costa JR; Silva NC; Sarmento B; Pintado M
    Curr Pharm Biotechnol; 2017; 18(2):108-120. PubMed ID: 27924724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.